Christine Maric1, Shannon Sullivan. 1. Department of Medicine, Georgetown University Medical Center, Washington, DC 20057, USA. cm255@georgetown.edu
Abstract
BACKGROUND: Across all ages, the incidence and rate of progression of most nondiabetic renal diseases are markedly higher in men compared with age-matched women. These observations suggest that female sex may be renoprotective. In the setting of diabetes, however, this female protection against the development and progression of renal disease is diminished. OBJECTIVE: This review aimed to summarize our current understanding of sex differences in the development and progression of diabetic renal disease, and of the contribution of sex hormones, particularly estrogens, to the pathophysiology of this disease. We also attempted to answer why female sex does not protect the diabetic kidney. METHODS: Using terms such as gender, sex, diabetes, diabetic nephropathy, estrogens, and sex hormones, the PubMed database was searched for English-language articles; targeted searches were conducted using terms such as gender/sex differences in diabetic renal disease. No restrictions were imposed on publication dates. RESULTS: Although the existing data regarding the sex differences in the incidence and progression of diabetic renal disease are inconclusive, the undisputed fact is that women with either type 1 or type 2 diabetes mellitus exhibit a much higher incidence of renal disease compared with nondiabetic women. It is conceivable that the loss of female sex as a renoprotective factor in diabetes may be related to the abnormal regulation of sex hormone concentrations. Both clinical and experimental data suggest that diabetes may be associated with an imbalance in estradiol concentrations. Supplementation with 17beta-estradiol or administration of selective estrogen receptor modulators reduces the incidence of diabetes and attenuates the progression of diabetic renal disease. CONCLUSIONS: Serum concentrations of ovarian hormones may provide a new means for predicting future risk of renal complications in diabetes. Exogenous steroid hormones may be an effective treatment for attenuating the progression of diabetic nephropathy.
BACKGROUND: Across all ages, the incidence and rate of progression of most nondiabetic renal diseases are markedly higher in men compared with age-matched women. These observations suggest that female sex may be renoprotective. In the setting of diabetes, however, this female protection against the development and progression of renal disease is diminished. OBJECTIVE: This review aimed to summarize our current understanding of sex differences in the development and progression of diabetic renal disease, and of the contribution of sex hormones, particularly estrogens, to the pathophysiology of this disease. We also attempted to answer why female sex does not protect the diabetic kidney. METHODS: Using terms such as gender, sex, diabetes, diabetic nephropathy, estrogens, and sex hormones, the PubMed database was searched for English-language articles; targeted searches were conducted using terms such as gender/sex differences in diabetic renal disease. No restrictions were imposed on publication dates. RESULTS: Although the existing data regarding the sex differences in the incidence and progression of diabetic renal disease are inconclusive, the undisputed fact is that women with either type 1 or type 2 diabetes mellitus exhibit a much higher incidence of renal disease compared with nondiabetic women. It is conceivable that the loss of female sex as a renoprotective factor in diabetes may be related to the abnormal regulation of sex hormone concentrations. Both clinical and experimental data suggest that diabetes may be associated with an imbalance in estradiol concentrations. Supplementation with 17beta-estradiol or administration of selective estrogen receptor modulators reduces the incidence of diabetes and attenuates the progression of diabetic renal disease. CONCLUSIONS: Serum concentrations of ovarian hormones may provide a new means for predicting future risk of renal complications in diabetes. Exogenous steroid hormones may be an effective treatment for attenuating the progression of diabetic nephropathy.
Authors: R Mangili; G Deferrari; U Di Mario; O Giampietro; R Navalesi; R Nosadini; G Rigamonti; R Spezia; G Crepaldi Journal: Diabetologia Date: 1994-10 Impact factor: 10.122
Authors: B A Coonrod; D Ellis; D J Becker; C H Bunker; S F Kelsey; C E Lloyd; A L Drash; L H Kuller; T J Orchard Journal: Diabetes Care Date: 1993-10 Impact factor: 19.112
Authors: H H Parving; M A Gall; P Skøtt; H E Jørgensen; H Løkkegaard; F Jørgensen; B Nielsen; S Larsen Journal: Kidney Int Date: 1992-04 Impact factor: 10.612
Authors: Regina F Sultanova; Ryan Schibalski; Irina A Yankelevich; Krisztian Stadler; Daria V Ilatovskaya Journal: Am J Physiol Renal Physiol Date: 2020-11-02
Authors: Yun Shen; Lizheng Shi; Elizabeth Nauman; Peter T Katzmarzyk; Eboni G Price-Haywood; Ping Yin; Alessandra N Bazzano; Somesh Nigam; Gang Hu Journal: J Diabetes Date: 2018-11-13 Impact factor: 4.006
Authors: Debra L Irsik; Melissa J Romero-Aleshire; Erin M Chavez; Rachel W Fallet; Heddwen L Brooks; Pamela K Carmines; Pascale H Lane Journal: Am J Physiol Renal Physiol Date: 2018-04-18
Authors: Khalid Al-Rubeaan; Amira M Youssef; Shazia N Subhani; Najlaa A Ahmad; Ahmad H Al-Sharqawi; Hind M Al-Mutlaq; Satish K David; Dhekra AlNaqeb Journal: PLoS One Date: 2014-02-21 Impact factor: 3.240